← Back to Screener
Genprex, Inc. Common Stock (GNPX)
Price$1.30
Favorite Metrics
Price vs S&P 500 (26W)-96.06%
Price vs S&P 500 (4W)-40.34%
Market Capitalization$11.76M
All Metrics
Book Value / Share (Quarterly)$0.76
P/TBV (Annual)3.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-15.02
Price vs S&P 500 (YTD)-29.85%
EPS (TTM)$-107.92
10-Day Avg Trading Volume0.44M
EPS Excl Extra (TTM)$-107.92
EPS (Annual)$-263.49
ROI (Annual)-1303.03%
Cash / Share (Quarterly)$1.10
ROA (Last FY)-511.87%
EBITD / Share (TTM)$-62.84
ROE (5Y Avg)-386.77%
Cash Flow / Share (Annual)$-78.95
P/B Ratio15.31x
P/B Ratio (Quarterly)9.47x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1404.94x
ROA (TTM)-386.95%
EPS Incl Extra (Annual)$-263.49
Current Ratio (Annual)0.83x
Quick Ratio (Quarterly)0.43x
3-Month Avg Trading Volume0.79M
52-Week Price Return-89.84%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.19
52-Week High$55.00
EPS Excl Extra (Annual)$-263.49
Tangible BV CAGR (5Y)-12.76%
26-Week Price Return-87.32%
Quick Ratio (Annual)0.64x
13-Week Price Return-54.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.67x
Enterprise Value$10.655
Book Value / Share Growth (5Y)3.53%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.37
3-Month Return Std Dev113.22%
Net Income / Employee (TTM)$-1
ROE (Last FY)-1303.03%
EPS Basic Excl Extra (Annual)$-263.49
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-107.92
Receivables Turnover (Annual)0.00x
ROI (TTM)-809.25%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.89
Price vs S&P 500 (52W)-124.94%
Year-to-Date Return-25.71%
5-Day Price Return7.44%
EPS Normalized (Annual)$-263.49
ROA (5Y Avg)-200.22%
Month-to-Date Return-28.18%
Cash Flow / Share (TTM)$-0.61
EBITD / Share (Annual)$-264.20
ROI (5Y Avg)-386.77%
EPS Basic Excl Extra (TTM)$-107.92
P/TBV (Quarterly)2.93x
P/B Ratio (Annual)4.47x
Book Value / Share (Annual)$7.46
Price vs S&P 500 (13W)-57.57%
Beta-0.71x
Revenue / Share (TTM)$0.00
ROE (TTM)-809.25%
52-Week Low$1.15
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GNPXGenprex, Inc. Common Stock | — | — | — | — | $1.30 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Genprex Inc develops non-viral gene therapies for cancer and diabetes. The company's Oncoprex Delivery System uses lipid nanoparticles to deliver therapeutic genes, with its lead candidate Reqorsa under evaluation in three clinical trials for non-small cell and small cell lung cancer.